Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: 9a4b1a16efbdf3027f5cf5307479ed0e30122b27
First added on: Feb 11, 2025